Abstract

Results. During one year period, 212 strains of E. coli and 103 strains of K. pneumoniae were isolated. Of these, the ESBL production was observed in 26 (11.8%) isolates of E. coli and 25 (24.3%) isolates of K. pneumoniae. ESBLproducing E. coli isolates were commonly recovered from the respiratory tract (21.4%) and urine (7.2%). ESBL-positive K. pneumoniae was commonly recovered from urine (38.5%) and respiratory tract (18.7%). ESBL-positive E. coli isolates were more susceptible to AMC (76%) and SXT (50%), than were the isolates of ESBLpositive K. pneumoniae (40% and 32%). Considering aminoglycosides, 92% of ESBL-positive E. coli and 60% of ESBL-positive K. pneumoniae were susceptible to amikacin vs. 23% and 40% of ESBL-positive E. coli and K. pneumoniae strains to gentamicin. ESBL-positive K. pneumoniae strains were more susceptible to ciprofloxacin (84%) than ESBL-positive strains of E. coli (38%). Cefepime shows the best in vitro activity of tested cephalosporins (58% for E. coli and 72% for K. pneumoniae). All isolates were susceptible to imipenem.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call